(Q43764381)

26 November 2017

title

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study (English)

1 reference

26 November 2017

0 references

1 reference

pulmonary hypertension

1 reference

R N Channick

1

1 reference

26 November 2017

G Simonneau

2

1 reference

26 November 2017

O Sitbon

3

1 reference

26 November 2017

I M Robbins

4

1 reference

26 November 2017

A Frost

5

1 reference

26 November 2017

V F Tapson

6

1 reference

26 November 2017

D B Badesch

7

1 reference

26 November 2017

S Roux

8

1 reference

26 November 2017

M Rainisio

9

1 reference

26 November 2017

F Bodin

10

1 reference

26 November 2017

L J Rubin

11

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

358

1 reference

26 November 2017

issue

9288

1 reference

26 November 2017

page(s)

1119-1123

1 reference

Primary pulmonary hypertension

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Orally active prostacyclin analogue in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin-1: a mediator of pulmonary hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin-1-like immunoreactivity in postobstructive pulmonary vasculopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Acute pro‐inflammatory actions of endothelin‐1 in the guinea‐pig lung: involvement of ETA and ETB receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Psychophysical bases of perceived exertion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin antagonism with bosentan: a review of potential applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Update of REACH-1 and MERIT-HF clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

EndothelinB receptor-mediated contraction in human pulmonary resistance arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Endothelin receptors in cultured adult rat cardiac fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

Role of endothelin in the increased vascular tone of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906250-X

7 January 2021

10.1016/S0140-6736(01)06250-X

Identifiers

DOI

1 reference

26 November 2017

1 reference